News | News By Subject | News by Disease News By Date | Search News

Gaucher's disease News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial     2/18/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Genzyme Corporation (GENZ)'s New Rare Disease Pill Will Cost Patients $310,250 A Year     9/5/2014
FDA Approves Genzyme Corporation (GENZ)'s Gaucher Disease Pill Cerdelga     8/20/2014
Genzyme Corporation (GENZ)'s Gaucher Pill Application Gets Priority FDA Review     12/11/2013
Protalix Biotherapeutics, Inc. (PLX) Signs $280 Million Brazilian Gaucher Deal     6/19/2013
Genzyme Corporation (GENZ) Touts Positive Ph3 Drug Data     2/19/2013
Sanofi (France) (SAN.PA)'s Gaucher Pill Meets Goal in Phase 3 Trial     10/2/2012
Pfizer Inc. (PFE), Protalix Biotherapeutics, Inc. (PLX) Wins FDA Nod for Gaucher Disease Drug; Genzyme Corporation (GENZ) Faces Competition     5/2/2012
AngioChem, GlaxoSmithKline (GSK) Form $331 Million Pact to Discover and Develop Treatments of Lysosomal Storage Diseases     2/27/2012
Protalix Biotherapeutics, Inc. (PLX): FDA Requests More Information On Gaucher's Drug     2/25/2011
Three-Year Data from Phase 2 Trial of Genzyme Corporation (GENZ) Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints     2/22/2011
Genzyme Corporation (GENZ) To End Rationing Of Cerezyme In September; U.S. Patients Can Resume Normal Dosing     8/26/2010

News from Around the Web

Press Releases
Genzyme (GENZ) Receives Innovation Award From The National Organization For Rare Disorders (NORD) For The Development Of Cerdelga     5/19/2015
Genzyme (GENZ) Release: ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (Eliglustat) For Treatment-Naïve Patients With Gaucher Disease Type 1 Published In JAMA     2/18/2015
Genzyme (GENZ) Presents Phase 3 Clinical Trial Extension Results For Cerdelga® (Eliglustat) At Lysosomal Disease Network’s WORLD Symposium 2015     2/12/2015
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting     6/23/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease     6/18/2014
Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients     5/30/2014
Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients     5/22/2014
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients     10/14/2013
Protalix Biotherapeutics, Inc. (PLX) Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease     4/2/2013
Protalix Biotherapeutics, Inc. (PLX) Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European Working Group on Gaucher Disease Meeting     7/2/2012
GlobalData Release: Elelyso: a New Therapeutic Option for Patients With Gaucher Disease     5/8/2012
Amicus Therapeutics, Inc. (FOLD) Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease     2/10/2012
Four-Year Data from Phase 2 Trial of Genzyme Corporation (GENZ) Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints     2/8/2012
Protalix Biotherapeutics, Inc. (PLX) Announces Successful GMP Manufacturing Audit by Brazil's National Health Surveillance Agency     6/15/2011
Protalix Biotherapeutics Presents Data on the Company's Fabry Program and Oral Enzyme Gaucher Program With Experts in the Field of Lysosomal Disorders     1/19/2011

//-->